Primary lacrimal sac melanoma: a case report describing the novel use of fine needle aspiration cytology (FNAC) for diagnosis, together with literature review and immunotherapy treatment update

References

• McGrath L, O’Hagan S. Malignant Melanoma of the Lacrimal Sac: case report and major review with treatment update. J Ophthalmol & Vis Neurosci. 2016;1(3):010.
   Google Scholar
• Vinciguerra A, Rampi A, Giordano Resti A, Barbieri D, Bussi M, Trimarchi M. Melanoma of the lacrimal drainage system: a systematic review. Head Neck. 2021;43(7):2240–2252. doi:10.1002/hed.26705
   PubMed Web of Science ®Google Scholar
• Matsuo T, Tanaka T, Yamasaki O. Lacrimal Sac Malignant melanoma in 15 Japanese patients: case report and literature review. J Investig Med High Impact Case Rep. 2019;7:2324709619888052. doi:10.1177/2324709619888052
   Web of Science ®Google Scholar
• Salloum G, Dryden S, Meador AG, Kurochkin PD, Chamberlain BK, Fasig JH, et al. Primary melanoma of the lacrimal sac treated with pembrolizumab. Ophthalmic Plast Reconstr Surg. 2021;37(3):e111–e2. doi:10.1097/IOP.0000000000001868
   PubMed Web of Science ®Google Scholar
• Zhao Y, Hui JW, Yang LL, Zhao H, Lin JY, Pan Y. [Clinical and pathological analysis of 64 patients with primary neoplasms of the lacrimal drainage system]. Zhonghua Yan Ke Za Zhi. 2020;56(5):364–369. doi:10.3760/cma.j.cn112142-20190414-00216
   PubMedGoogle Scholar
• Song X, Wang J, Wang S, Wang W, Zhu W. Clinical analysis of 90 cases of malignant lacrimal sac tumor. Graefes Arch Clin Exp Ophthalmol. 2018;256(7):1333–1338. doi:10.1007/s00417-018-3962-4
   PubMed Web of Science ®Google Scholar
• Stefanyszyn MA, Hidayat AA, Pe’Er JJ, Flanagan JC. Lacrimal sac tumors. Ophthalmic Plast Reconstr Surg. 1994;10(3):169–184. doi:10.1097/00002341-199409000-00005
   PubMed Web of Science ®Google Scholar
• Brierley JD, Gospodarowicz MK, Wittekind CH. Union for International Cancer Control. TNM Classification of Malignant Tumours. 8th ed. Oxford: WILEY Blackwell; 2017:131–138.
   Google Scholar
• Lewis AM, Clarke PM, Olver JM. Primary nasolacrimal duct malignant mucosal melanoma. Br J Ophthalmol. 2006;90(1):114–115. doi:10.1136/bjo.2005.073239
   PubMed Web of Science ®Google Scholar
• Tyrrell H, Payne M. Combatting mucosal melanoma: recent advances and future perspectives. Melanoma Manag. 2018;5(3):MMT11. doi:10.2217/mmt-2018-0003
   PubMed Web of Science ®Google Scholar
• Lyu J, Wu Y, Li C, Wang R, Song H, Ren G, et al. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases. J Oral Pathol Med. 2016;45(4):295–301. doi:10.1111/jop.12358
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Accorona R, Botti G, Farina D, Fossati P, Gatta G, et al. Mucosal melanoma of the head and neck. Crit Rev Oncol Hematol. 2017;112:136–152. doi:10.1016/j.critrevonc.2017.01.019
   PubMed Web of Science ®Google Scholar
• Tacastacas JD, Bray J, Cohen YK, Arbesman J, Kim J, Koon HB, et al. Update on primary mucosal melanoma. J Am Acad Dermatol. 2014;71(2):366–375. doi:10.1016/j.jaad.2014.03.031
   PubMed Web of Science ®Google Scholar
• Cancer Research United Kingdom. Skin cancer incidence statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk2021. Accessed June 14, 2022.
   Google Scholar
• Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664–1678. doi:10.1002/(SICI)1097-0142(19981015)83:8<1664:AID-CNCR23>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Lian B, Cui CL, Zhou L, Song X, Zhang XS, Wu D, et al. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. Ann Oncol. 2017;28(4):868–873. doi:10.1093/annonc/mdw694
   PubMed Web of Science ®Google Scholar
• Furney SJ, Turajlic S, Stamp G, Nohadani M, Carlisle A, Thomas JM, et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol. 2013;230(3):261–269. doi:10.1002/path.4204
   PubMed Web of Science ®Google Scholar
• Hoyt DJ, Jordan T, Fisher SR. Mucosal melanoma of the head and neck. Arch Arch Otolaryngol Head Neck Surg. 1989;115(9):1096–1099. 10.1001/archotol.1989.01860330086023
   PubMedGoogle Scholar
• Altieri L, Wong MK, Peng DH, Cockburn M. Mucosal melanomas in the racially diverse population of California. J Am Acad Dermatol. 2017;76(2):250–257. doi:10.1016/j.jaad.2016.08.007
   PubMed Web of Science ®Google Scholar
• Hahn HM, Lee KG, Choi W, Cheong SH, Myung KB, Hahn HJ. An updated review of mucosal melanoma: survival meta-analysis. Mol Clin Oncol. 2019;11(2):116–126. doi:10.3892/mco.2019.1870
   PubMed Web of Science ®Google Scholar
• Pujari A, Ali MJ, Mulay K, Naik MN, Honavar SG. The black lacrimal sac: a clinicopathological correlation of a malignant melanoma with anterior lacrimal crest infiltration. Int Ophthalmol. 2014;34(1):111–115. doi:10.1007/s10792-013-9743-5
   PubMed Web of Science ®Google Scholar
• Lloyd WC, Leone CR. Malignant melanoma of the lacrimal sac. Arch Ophthalmol. 1984;102(1):104–107. doi:10.1001/archopht.1984.01040030088043
   PubMedGoogle Scholar
• Heindl LM, Jünemann AG, Kruse FE, Holbach LM. Tumors of the lacrimal drainage system. Orbit. 2010;29(5):298–306. doi:10.3109/01676830.2010.492887
   PubMedGoogle Scholar
• Thoelke A, Willrodt S, Hauschild A, Schadendorf D. Primary extracutaneous malignant melanoma: a comprehensive review with emphasis on treatment. Onkologie. 2004;27(5):492–499. doi:10.1159/000080372
   PubMedGoogle Scholar
• Ramberg I, Toft PB, Heegaard S. Carcinomas of the lacrimal drainage system. Surv Ophthalmol. 2020;65(6):691–707. doi:10.1016/j.survophthal.2020.04.001
   PubMed Web of Science ®Google Scholar
• Flanagan JC, Stokes DP. Lacrimal sac tumors. Ophthalmology. 1978;85(12):1282–1287. doi:10.1016/S0161-6420(78)35554-8
   PubMed Web of Science ®Google Scholar
• Nam JH, Kim SM, Choi JH, Lee YK, Baek JH, Jang TJ, et al. Primary malignant melanoma of the lacrimal sac: a case report. Korean J Intern Med. 2006;21(4):248–251. doi:10.3904/kjim.2006.21.4.248
   PubMedGoogle Scholar
• Subramaniam SS, Anand R, Mellor TK, Brennan PA. Primary Lacrimal Sac Melanoma with Metastatic Cervical Disease: a Review of the Literature and Case Report. J Oral Maxillofac Surg. 2017;75(7):1438–1441. doi:10.1016/j.joms.2017.01.015
   PubMed Web of Science ®Google Scholar
• Sendra Tello J, Galindo Campillo N, Rodriguez-Peralto JL, Alvarez-Linera J, Garabito Cocina I. Malignant melanoma of the lacrimal sac. Otolaryngol Head Neck Surg. 2004;131(3):334–336. doi:10.1016/j.otohns.2003.09.023
   PubMed Web of Science ®Google Scholar
• Lee HM, Kang HJ, Choi G, Chae SW, Kim CH, Hwang SJ, et al. Two cases of primary malignant melanoma of the lacrimal sac. Head Neck. 2001;23(9):809–813. doi:10.1002/hed.1116
   PubMed Web of Science ®Google Scholar
• Owens RM, Wax MK, Kostik D, Linberg JV, Hogg J. Malignant melanoma of the lacrimal sac. Otolaryngol Head Neck Surg. 1995;113(5):634–640. doi:10.1177/019459989511300520
   PubMed Web of Science ®Google Scholar
• Kavoussi SC, Levin F, Servat JJ. Orbital Extension of Untreated Lacrimal Sac Melanoma Following Dacryocystorhinostomy. Ophthalmic Plast Reconstr Surg. 2016;32(3):e76. doi:10.1097/IOP.0000000000000539
   PubMed Web of Science ®Google Scholar
• Lu H, Yao M, Anderson K, Buatti J. Optically guided stereotactic radiotherapy for lacrimal sac tumors: a report on two cases. Technol Cancer Res Treat. 2008;7(1):35–40. doi:10.1177/153303460800700104
   PubMed Web of Science ®Google Scholar
• Nenclares P, Ap Dafydd D, Bagwan I, Begg D, Kerawala C, King E, et al. Head and neck mucosal melanoma: the United Kingdom national guidelines. Eur J Cancer. 2020;138:11–18. doi:10.1016/j.ejca.2020.07.017
   PubMed Web of Science ®Google Scholar
• Tani E, Seregard S, Rupp G, Söderlund V, Skoog L. Fine-Needle aspiration cytology and immunocytochemistry of orbital masses. Diagn Cytopathol. 2006;34(1):1–5. doi:10.1002/dc.20375
   PubMed Web of Science ®Google Scholar
• Agrawal P, Dey P, Lal A. Fine-Needle aspiration cytology of orbital and eyelid lesions. Diagn Cytopathol. 2013;41(11):1000–1011. doi:10.1002/dc.22972
   PubMed Web of Science ®Google Scholar
• Khan L, Malukani K, Malaiya S, Yeshwante P, Ishrat S, Nandedkar SS. Role of fine needle aspiration cytology as a diagnostic tool in orbital and Adnexal Lesions. J Ophthalmic Vis Res. 2016;11(3):287–295. doi:10.4103/2008-322X.188397
   PubMedGoogle Scholar
• Tijl JW, Koornneef L. Fine needle aspiration biopsy in orbital tumours. Br J Ophthalmol. 1991;75(8):491–492. doi:10.1136/bjo.75.8.491
   PubMed Web of Science ®Google Scholar
• Zajdela A, Vielh P, Schlienger P, Haye C. Fine-Needle cytology of 292 palpable orbital and eyelid tumors. Am J Clin Pathol. 1990;93(1):100–104. doi:10.1093/ajcp/93.1.100
   PubMed Web of Science ®Google Scholar
• Nair LK, Sankar S. Role of fine needle aspiration cytology in the diagnosis of orbital masses: a study of 41 cases. J Cytol. 2014;31(2):87–90. doi:10.4103/0970-9371.138672
   PubMed Web of Science ®Google Scholar
• Solo S, Siddaraju N, Srinivasan R. Use of fine needle cytology in the diagnosis of orbital and eyelid mass lesions. Acta Cytol. 2009;53(1):41–52. doi:10.1159/000325084
   PubMed Web of Science ®Google Scholar
• Singhal N, Mundi IK, Handa U, Punia RP, Mohan H. FNA in diagnosis of orbital lesions causing proptosis in adults. Diagn Cytopathol. 2012;40(10):861–864. doi:10.1002/dc.21649
   PubMed Web of Science ®Google Scholar
• Zeppa P, Tranfa F, Errico ME, Troncone G, Fulciniti F, Vetrani A, et al. Fine needle aspiration (FNA) biopsy of orbital masses: a critical review of 51 cases. Cytopathology. 1997;8(6):366–372. doi:10.1111/j.1365-2303.1997.tb00566.x
   PubMed Web of Science ®Google Scholar
• Cangiarella JF, Cajigas A, Savala E, Elgert P, Slamovits TL, Suhrland MJ. Fine needle aspiration cytology of orbital masses. Acta Cytol. 1996;40(6):1205–1211. doi:10.1159/000333981
   PubMed Web of Science ®Google Scholar
• Das DK, Das J, Bhatt NC, Chachra KL, Natarajan R. Orbital lesions. Diagnosis by fine needle aspiration cytology. Acta Cytol. 1994;38:158–164.
   PubMed Web of Science ®Google Scholar
• Dey P, Radhika S, Rajwanshi A, Ray R, Nijhawan R, Das A. Fine needle aspiration biopsy of orbital and eyelid lesions. Acta Cytol. 1993;37:903–907.
   PubMed Web of Science ®Google Scholar
• Glasgow BJ, Layfield LJ. Fine-Needle aspiration biopsy of orbital and periorbital masses. Diagn Cytopathol. 1991;7(2):132–141. 10.1002/dc.2840070206
   PubMed Web of Science ®Google Scholar
• Arora R, Rewari R, Betharia SM. Fine needle aspiration cytology of orbital and adnexal masses. Acta Cytol. 1992;36:483–491.
   PubMed Web of Science ®Google Scholar
• Roskell DE, Buley ID. Fine needle aspiration cytology in cancer diagnosis. BMJ. 2004;329(7460):244–245. doi:10.1136/bmj.329.7460.244
   PubMedGoogle Scholar
• Murali R, Doubrovsky A, Watson GF, McKenzie PR, Lee CS, McLeod DJ, et al. Diagnosis of metastatic melanoma by fine-needle biopsy: analysis of 2,204 cases. Am J Clin Pathol. 2007;127(3):385–397. doi:10.1309/3QR4FC5PPWXA7N29
   PubMed Web of Science ®Google Scholar
• Singh N, Ryan D, Berney D, Calaminici M, Sheaff MT, Wells CA. Inadequate rates are lower when FNAC samples are taken by cytopathologists. Cytopathology. 2003;14(6):327–331. doi:10.1046/j.0956-5507.2003.00084.x
   PubMed Web of Science ®Google Scholar
• Shields JA, Shields CL, Ehya H, Eagle RC, De Potter P. Fine-Needle aspiration biopsy of suspected intraocular tumors. Int Ophthalmol Clin. 1993;33(3):77–82. doi:10.1097/00004397-199303330-00012
   PubMedGoogle Scholar
• Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, et al. Next-Generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014;27(2):314–327. doi:10.1038/modpathol.2013.122
   PubMed Web of Science ®Google Scholar
• Balla A, Hampel KJ, Sharma MK, Cottrell CE, Sidiropoulos N. Comprehensive Validation of Cytology Specimens for Next-Generation Sequencing and Clinical Practice Experience. J Mol Diagn. 2018;20(6):812–821. doi:10.1016/j.jmoldx.2018.06.001
   PubMedGoogle Scholar
• Wei S, Lieberman D, Morrissette JJ, Baloch ZW, Roth DB, McGrath C. Using “residual” FNA rinse and body fluid specimens for next-generation sequencing: an institutional experience. Cancer Cytopathol. 2016;124(5):324–329. doi:10.1002/cncy.21666
   PubMed Web of Science ®Google Scholar
• Wiktorin ACH, Dafgård Kopp EME, Tani E, Söderén B, Allen RC. Fine-Needle Aspiration Biopsy in Orbital Lesions: a Retrospective Study of 225 Cases. Am J Ophthalmol. 2016;166:37–42. doi:10.1016/j.ajo.2016.03.021
   PubMed Web of Science ®Google Scholar
• Shah KS, Ethunandan M. Tumour seeding after fine-needle aspiration and core biopsy of the head and neck–a systematic review. Br J Oral Maxillofac Surg. 2016;54(3):260–265. doi:10.1016/j.bjoms.2016.01.004
   PubMed Web of Science ®Google Scholar
• Shyamala K, Girish HC, Murgod S. Risk of tumor cell seeding through biopsy and aspiration cytology. J Int Soc Prev Community Dent. 2014;4(1):5–11. doi:10.4103/2231-0762.129446
   PubMedGoogle Scholar
• Dyavanagoudar S, Kale A, Bhat K, Hallikerimath S. Reverse transcriptase polymerase chain reaction study to evaluate dissemination of cancer cells into circulation after incision biopsy in oral squamous cell carcinoma. Indian J Dent Res. 2008;19(4):315–319. doi:10.4103/0970-9290.44534
   PubMedGoogle Scholar
• Kusukawa J, Suefuji Y, Ryu F, Noguchi R, Iwamoto O, Kameyama T. Dissemination of cancer cells into circulation occurs by incisional biopsy of oral squamous cell carcinoma. J Oral Pathol Med. 2000;29(7):303–307. doi:10.1034/j.1600-0714.2000.290703.x
   PubMed Web of Science ®Google Scholar
• Kennerdell JS, Slamovits TL, Dekker A, Johnson BL. Orbital fine-needle aspiration biopsy. Am J Ophthalmol. 1985;99(5):547–551. doi:10.1016/S0002-9394(14)77955-3
   PubMed Web of Science ®Google Scholar
• Midena E, Segato T, Piermarocchi S, Boccato P. Fine needle aspiration biopsy in ophthalmology. Surv Ophthalmol. 1985;29(6):410–422. doi:10.1016/0039-6257(85)90206-1
   PubMed Web of Science ®Google Scholar
• Liu D. Complications of fine needle aspiration biopsy of the orbit. Ophthalmology. 1985;92(12):1768–1771. doi:10.1016/S0161-6420(85)34106-4
   PubMed Web of Science ®Google Scholar
• Lau RP, Chiaffarano J, Alexander M, Octavius J, Azar O, Shi Y, et al. Primary anorectal mucosal melanoma detected by anorectal cytology. Diagn Cytopathol. 2017;45(5):452–455. doi:10.1002/dc.23675
   PubMed Web of Science ®Google Scholar
• Koss L, Myron M. Diagnostic Cytology and Its Histological Basis. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006:5–6.
   Google Scholar
• Canti G. Skin cytology and its value for rapid diagnosis. Acta Cytol; 1979; 23: 519
   Web of Science ®Google Scholar
• Carvajal RD, Spencer SA, Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. J Natl Compr Canc Netw. 2012;10(3):345–356. doi:10.6004/jnccn.2012.0034
   PubMed Web of Science ®Google Scholar
• Kline TS, Kannan V. Aspiration biopsy cytology and melanoma. Am J Clin Pathol. 1982;77(5):597–601. doi:10.1093/ajcp/77.5.597
   PubMed Web of Science ®Google Scholar
• Levine MR, Dinar Y, Davies R. Malignant melanoma of the lacrimal sac. Ophthalmic Surg Lasers. 1996;27(4):318–320. doi:10.3928/1542-8877-19960401-13
   PubMedGoogle Scholar
• Seifried S, Haydu LE, Quinn MJ, Scolyer RA, Stretch JR, Thompson JF. Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases. Ann Surg Oncol. 2015;22(6):1959–1966. doi:10.1245/s10434-014-4215-3
   PubMed Web of Science ®Google Scholar
• Nilsson PJ, Ragnarsson-Olding BK. Importance of clear resection margins in anorectal malignant melanoma. Br J Surg. 2010;97(1):98–103. doi:10.1002/bjs.6784
   PubMed Web of Science ®Google Scholar
• Yde SS, Sjoegren P, Heje M, Stolle LB. Mucosal Melanoma: a Literature Review. Curr Oncol Rep. 2018;20(3):28. doi:10.1007/s11912-018-0675-0
   PubMed Web of Science ®Google Scholar
• Penel N, Mallet Y, Mirabel X, Van JT, Lefebvre JL. Primary mucosal melanoma of head and neck: prognostic value of clear margins. Laryngoscope. 2006;116(6):993–995. doi:10.1097/01.mlg.0000217236.06585.a9
   PubMed Web of Science ®Google Scholar
• Lee SP, Shimizu KT, Tran LM, Juillard G, Calcaterra TC. Mucosal melanoma of the head and neck: the impact of local control on survival. Laryngoscope. 1994;104(2):121–126. doi:10.1288/00005537-199402000-00001
   PubMed Web of Science ®Google Scholar
• Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer. 1997;80(8):1373–1386. doi:10.1002/(SICI)1097-0142(19971015)80:8<1373:AID-CNCR3>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Lee G, Baek CH, Choi NY, Chung MK. The prognostic role of the surgical approach and adjuvant therapy in operable mucosal melanoma of the head and neck. Clin Exp Otorhinolaryngol. 2017;10(1):97–103. doi:10.21053/ceo.2016.00094
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, et al. Phase II study of nilotinib in melanoma harboring kit alterations following progression to prior kit inhibition. Clin Cancer Res. 2015;21(10):2289–2296. doi:10.1158/1078-0432.CCR-14-1630
   PubMed Web of Science ®Google Scholar
• Kremenovic M, Schenk M, Lee DJ. Clinical and molecular insights into BCG immunotherapy for melanoma. J Intern Med. 2020;288(6):625–640. doi:10.1111/joim.13037
   PubMed Web of Science ®Google Scholar
• Yamade S, Kitagawa A. Malignant melanoma of the lacrimal sac. Ophthalmologica. 1978;177(1):30–33. doi:10.1159/000308733
   PubMed Web of Science ®Google Scholar
• Nakamura S, Takeda K, Tanaka R, Araki Y. Two cases of malignant melanoma of the lacrimal sac. Folia Ophthalmologica Japonica. 2007;58:561–566.
   Google Scholar
• Maegawa J, Yasumura K, Iwai T, Hata M, Inayama Y, Kobayashi S. Malignant melanoma of the lacrimal sac: a case report. Int J Dermatol. 2014;53(2):243–245. doi:10.1111/j.1365-4632.2012.05480.x
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384. doi:10.1016/S1470-2045(15)70076-8
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017. doi:10.1056/NEJMoa1414428
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. doi:10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030. doi:10.1200/JCO.2013.53.0105
   PubMed Web of Science ®Google Scholar
• Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017;86:37–45. doi:10.1016/j.ejca.2017.07.022
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, et al. Efficacy and Safety of Nivolumab Alone or in Combination with Ipilimumab in Patients with Mucosal Melanoma: a Pooled Analysis. J Clin Oncol. 2017;35(2):226–235. doi:10.1200/JCO.2016.67.9258
   PubMed Web of Science ®Google Scholar
• Johnson DC, Elvin JA. Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes. J Clin Oncol. 2017;35(15_suppl):9536–9600. 10.1200/JCO.2017.35.15_suppl.9536
   Google Scholar
• Cheng TW, Yu NY, Seetharam M, Patel SH. Radiotherapy for malignant melanoma of the lacrimal sac. Rare Tumors. 2020;12:2036361320971943. doi:10.1177/2036361320971943
   Web of Science ®Google Scholar
• Ma Y, Xia R, Ma X, Judson-Torres RL, Zeng H. Mucosal melanoma: pathological evolution, pathway dependency and targeted therapy. Front Oncol. 2021;11:702287. doi:10.3389/fonc.2021.702287
   PubMed Web of Science ®Google Scholar
• Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, et al. Whole-Genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019;10(1):3163. doi:10.1038/s41467-019-11107-x
   PubMedGoogle Scholar
• Dumaz N, Jouenne F, Delyon J, Mourah S, Bensussan A, Lebbé CA. Atypical. Cancers (Basel). 2019;11(8).
   Google Scholar
• Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182–3190. doi:10.1200/JCO.2012.47.7836
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. Jama. 2011;305(22):2327–2334. doi:10.1001/jama.2011.746
   PubMed Web of Science ®Google Scholar
• Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904–2909. doi:10.1200/JCO.2010.33.9275
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, et al. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer. 2017;123(14):2688–2697. doi:10.1002/cncr.30663
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14(3):249–256. doi:10.1016/S1470-2045(13)70024-X
   PubMed Web of Science ®Google Scholar
• Cosgarea I, Ugurel S, Sucker A, Livingstone E, Zimmer L, Ziemer M, et al. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations. Oncotarget. 2017;8(25):40683–40692. doi:10.18632/oncotarget.16542
   PubMed Web of Science ®Google Scholar
• Py C, Christinat Y, Kreutzfeldt M, McKee T, Dietrich P-Y, Tsantoulis P. Response of NF1- Mutated Melanoma to an MEK Inhibitor. JCO Precision Oncology. 2018(2):1–11. doi:10.1200/PO.18.00028
   PubMedGoogle Scholar
• Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, et al. Long-Term Outcomes in Patients with BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined with Trametinib. J Clin Oncol. 2018;36(7):667–673. doi:10.1200/JCO.2017.74.1025
   PubMed Web of Science ®Google Scholar
• Fujisawa Y, Ito T, Kato H, Irie H, Kaji T, Maekawa T, et al. Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: an analysis of 112 cases. Eur J Cancer. 2021;145:210–220. doi:10.1016/j.ejca.2020.12.021
   PubMed Web of Science ®Google Scholar
• Schuler MH, Ascierto PA, Fyfld V, Postow MA, Cml-V H, Carlino MS, et al. Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: safety, efficacy, and recommended phase 2 dose (RP2D). J Clin Oncol. 2017;35(15_suppl):9519–9600. doi:10.1200/JCO.2017.35.15_suppl.9519
   Google Scholar
• Sosman JA, Kittaneh M, Lolkema MPJK, Postow MA, Schwartz G, Franklin C, et al. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity. J Clin Oncol. 2014;32(15_suppl):9009–9510. doi:10.1200/jco.2014.32.15_suppl.9009
   Web of Science ®Google Scholar
• Wei BR, Hoover SB, Peer CJ, Dwyer JE, Adissu HA, Shankarappa P, et al. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. Mol Cancer Ther. 2020;19(11):2308–2318. doi:10.1158/1535-7163.MCT-19-0858
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626–636. doi:10.1056/NEJMoa1904059
   PubMed Web of Science ®Google Scholar
• Spencer KR, Mehnert JM. Mucosal Melanoma: epidemiology, Biology and Treatment. Cancer Treat Res. 2016;167:295–320.
   PubMedGoogle Scholar
• Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010;80(5):568–574. doi:10.1016/j.bcp.2010.04.032
   PubMed Web of Science ®Google Scholar
• Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013;31(14):1767–1774. doi:10.1200/JCO.2012.44.7888
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516. doi:10.1056/NEJMoa1103782
   PubMed Web of Science ®Google Scholar